GENFIT announces its upcoming participation in a number of investor and NASH-specific events over the next two months
Lille (France), Cambridge (Massachusetts, United States), August 31, 2018 – GENFIT (Euronext: GNFT - ISIN: FR0004163111), is a biopharmaceutical company focused on discovering and developing drug candidates and diagnostic solutions targeting liver diseases, in particular those of metabolic origin, and hepatobiliary diseases today announces its participation in numerous investor healthcare conferences both in Europe and the United States.
NASH is a fast evolving sector with numerous ongoing programs led by prominent pharmaceutical and biotechnology companies, all seeking to address the significant unmet medical need and growing burden on the healthcare system caused by this disease. Upcoming clinical milestones put NASH in the spotlight among the stakeholders which include the scientific community, media and investors.
Among those milestones, three programs (GENFIT, GILEAD and INTERCEPT PHARMACEUTICALS) have achieved full patient enrollment (Subpart H) for their on-going phase 3 trial in NASH, and should announce top-line results as early as next year that could lead to the first FDA- and EMAapproved drugs in the NASH space.
Of these most advanced molecules, GENFIT’s elafibranor is the only drug-candidate that has been able to show in a Phase 2b trial (Ratziu et al., Gastroenterology, 2016) a combination of:
- Efficacy on “NASH resolution without worsening of fibrosis” (26% vs 5%; p-value 0,02): o biopsy-based regulatory approved endpoint for phase 3 clinical trials o based on a strong rationale, as reducing hepatocellular ballooning and inflammation is known to be correlated with fibrosis improvement - Beneficial cardiovascular profile (LDL, TG, HDL, insulin resistance) - Clean safety and tolerability
In addition, new data releases from early phase (2a, 2b) clinical trials in NASH from companies like MADRIGAL and GALMED show that “resolving NASH” is a top priority for the whole NASH field.
Investors attending major European and American financial events over the next two months will be able to meet with GENFIT management, in a context characterized by upcoming data from clinical trials evaluating elafibranor in PBC (phase 2a) and NASH (phase 3).
UNITED STATES
- Rodman & Renshaw Global Investment Conference September 4-6, 2018 – New York, NY, United States
- Wells Fargo Healthcare conference September 5-6, 2018 – Boston, MA, United-States
- Morgan Stanley Global Healthcare Conference September 12-14, 2018 – New York, NY, United States